Bibliography
- Farber S , DiamondLK, MercerRD, SylvesterRF, WolffJA: Temporary remissions in acute leukemia in children produced by folic acid antagonist 4-aminopteroylglutamic acid (aminopterin).N. Engl. J. Med.238 , 787–793 (1948).
- Schmiegelow K : Advances in individual prediction of methotrexate toxicity: a review.Br. J. Haematol.146 , 489–503 (2009).
- Braun J , RauR: An update on methotrexate.Curr. Opin. Rheumatol.21 , 216–223 (2009).
- Davidsen ML , DalhoffK, SchmiegelowK: Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia.J. Pediatr. Hematol. Oncol.30 , 831–849 (2008).
- Dervieux T , GreensteinN, KremerJ: Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.Arthritis Rheum.54 , 3095–3103 (2006).
- Krajinovic M , MoghrabiA: Pharmacogenetics of methotrexate.Pharmacogenomics5 , 819–834 (2004).
- Toffoli G , RussoA, InnocentiF et al.: Effect of methylenetetrahydrofolate reductase 677C-->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients.Int. J. Cancer103 , 294–299 (2003).
- Patino-Garcia A , ZalacainM, MarrodanL, San-JulianM, SierrasesumagaL: Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.J. Pediatr.154(5) , 688–693 (2009).
- Ranganathan P : An update on methotrexate pharmacogenetics in rheumatoid arthritis.Pharmacogenomics9 , 439–451 (2008).
- Campalani E , ArenasM, MarinakiAM, LewisCM, BarkerJN, SmithCH: Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis.J. Invest. Dermatol.127 , 1860–1867 (2007).
- Herrlinger KR , CummingsJR, BarnardoMC, SchwabM, AhmadT, JewellDP: The pharmacogenetics of methotrexate in inflammatory bowel disease.Pharmacogenet. Genomics15 , 705–711 (2005).
- Ulrich CM , YasuiY, StorbR et al.: Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism.Blood98 , 231–234 (2001).
- Robien K , BiglerJ, YasuiY et al.: Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia.Biol. Blood Marrow Transplant.12 , 973–980 (2006).
- Whittle SL , HughesRA: Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review.Rheumatology (Oxford)43 , 267–271 (2004).
- Hayashi H , FujimakiC, DaimonT, TsuboiS, MatsuyamaT, ItohK: Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis.J. Clin. Pharm. Ther.34 , 355–361 (2009).
- Belkov VM , KrynetskiEY, SchuetzJD et al.: Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation.Blood93 , 1643–1650 (1999).
- Wessels JA , HuizingaTW, GuchelaarHJ: Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis.Rheumatology (Oxford)47 , 249–255 (2008).
- Bokkerink JP , DamenFJ, HulscherMW, BakkerMA, De Abreu RA: Biochemical evidence for synergistic combination treatment with methotrexate and 6-mercaptopurine in acute lymphoblastic leukemia. Hamatol. Bluttransfus.33 , 110–117 (1990).
- de Jonge R , TissingWJ, HooijbergJH et al.: Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia.Blood113 , 2284–2289 (2009).
- Deeken J : The Affymetrix DMET platform and pharmacogenetics in drug development.Curr. Opin. Mol. Ther.11 , 260–268 (2009).
- Schmiegelow K , ForestierE, KristinssonJ et al.: Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.Leukemia3 , 557–564 (2009).
- Schmiegelow K , SchroderH, GustafssonG et al.: Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology.J. Clin. Oncol.13 , 345–351 (1995).
- Campana D : Minimal residual disease in acute lymphoblastic leukemia.Semin. Hematol.46 , 100–106 (2009).
- Schmiegelow K , PulczynskaMK: Maintenance chemotherapy for childhood acute lymphoblastic leukemia: should dosage be guided by white blood cell counts?Am. J. Pediatr. Hematol. Oncol.12 , 462–467 (1990).